Vita Coco Q2 2026 slides: 28% sales growth, margins surge to 49%

Vita Coco (COCO) posted Q2 2026 net sales of $216M (+28.1% YoY) and EPS of $0.82 vs $0.5545 consensus, while gross margin jumped 1,240 bps to 48.7% and adjusted EBITDA margin rose to 31.1%. The company raised full-year 2026 guidance to $790–805M net sales and $154–161M adjusted EBITDA (gross margin ~40%), with the recently closed Copra acquisition expected to add >$100M in 2026 net sales. Balance sheet strength supported capital returns ($279M cash, zero debt; $44M repurchased vs $105M authorized), though management flagged cost pressures and ~95% capacity utilization that constrain near-term growth.

Analysis

The real story is not top-line growth; it is that earnings power is being temporarily inflated by a favorable input-cost mix that is unlikely to persist at the same rate. That matters because the equity is already pricing a clean compounding story, so any normalization in freight, packaging, or tariff refunds can compress forward EPS growth much faster than revenue growth slows. In other words, the stock is now more sensitive to gross-margin slope than to category demand.

Competitive dynamics are favorable for the category, but not automatically for every participant. The biggest second-order winner is likely retail shelf productivity: premium beverage space should keep expanding, while legacy sports/energy brands face share pressure if coconut water continues to take household penetration. The risk for the company is that private label and super-premium extensions can increase category visibility but also dilute mix over time, especially if the core brand has to fund more distribution and capacity before the next leg of volume arrives.

The key catalyst path is 1-3 months, not years: investors will focus on whether 2H guidance proves conservative on cost inflation or whether management is forced to revisit price in early 2027. The structural risk over 6-18 months is capacity; near-full utilization limits the company’s ability to monetize demand spikes without capex, which can flatten the operating leverage story. Consensus may be underestimating how quickly a 54x multiple can de-rate if margins merely move from exceptional to good.

Key Decisions for Investors

• Do not chase COCO at current levels; buy only on a 5-8% pullback or after a confirmation quarter that gross margin can hold above 42%. The setup is better as a wait-for-entry than an immediate momentum long because the guide implies margin deceleration into 2H26.
• Relative-value idea: long COCO / short MNST for 1-3 months if you want category-share exposure. Thesis: coconut water continues taking share from energy drinks, but COCO has the stronger near-term growth profile and clearer operating leverage; stop if COCO loses the 40% gross-margin floor or growth drops below the low-20s.
• If you need a hedge against multiple compression, buy COCO 60-90 day put spreads rather than shorting outright. The risk/reward is attractive because the downside catalyst is a simple margin reset, while upside is already constrained by a stretched valuation.
• Watch item, not trade: if management signals earlier-than-expected pricing actions in early 2027, that is the trigger to re-underwrite the EBITDA margin path. A failure to lift ACV or household penetration in the next scanner read would falsify the bull case faster than any macro variable.